THC hemisuccinate

THC hemisuccinate

The Solution to the Medicinal Cannabis Problem

Published in Michael E. Schatman, Ethical Issues in Chronic Pain Management, 2016

Other THC delivery forms are in early research stages. THC hemisuccinate suppositories are twice as bioavailable as oral THC (52–55), but have not been assayed in RCTs of pain, and may not prove to be acceptable as a delivery method by consumers in the United States. THC skin patches are currently under investigation, but available PK data (56,57) indicate that serum delivery attained to date is only a fraction of that required to produce therapeutic effects. The gradient required to obtain THC delivery transcutaneously ensures that a large residual fraction would be left in the patch, and represent a diversion risk upon disposal.

Medicinal cannabis pharmacokinetics and potential methods of delivery

View Article

Journal Information

Published in Pharmaceutical Development and Technology, 2022

Lidya Kebede, Seyedehsara Masoomi Dezfooli, Ali Seyfoddin

A pilot study consisting of two subjects, patient A and patient B, presented the pharmacokinetics following an administration of THC hemisuccinate suppository and oral Marinol THC. From Tables 5 and 6, the low plasma levels of THC–COOH, after a rectal administration indicates lower levels of drug metabolism. The relative bioavailability of rectal administration was determined to be higher compared to the oral route which is believed to be due to lower first-pass metabolism and higher absorption levels (Brenneisen et al. 1996).

Explore chapters and articles related to this topic

The Solution to the Medicinal Cannabis Problem

Medicinal cannabis pharmacokinetics and potential methods of delivery